Interview: Prof. Dr. Murat Özgören – Vice-Rector, Dokuz Eylül…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Dokuz Eylül Health Technopark DEPARK
The first thematic health technopark in Turkey that is fully integrated with hospital, research centers and medical schools. It is an ideal location for biotech and medical device companies inb Turkey for R&D, product development and soft-landing. DEPARK has started medical technopark services at its mother building ZEYTIN. The name zeytin refers to olives and it stands for 3500 years lifespan of olive trees while still producing olives. It also refers to natural health remedies that are attached to the olive (e.g. as in the movie Lorenzo’s Oil). There is a specifically medicine oriented technology transfer office called DETTO (Dokuz Eylül Technology Transfer Office). It has a wide variety of services from international soft landing, tax and law support, IP rights management, incubation, technical consultancy, funding, clinical trials, pre-clinical consultation to marketing and guidance for international partnering. The hosting university, Dokuz Eylül University, has 14 faculties (app 67,000 students) to support the larger ecosystem for a wide range of activities and research. The ecosystem includes a university hospital over 1,100 beds, medical school, medical graduate study programs, medical research institutes (ie oncology, genome etc), nearly 1,000 academics, health technologies accelerator, associate service study programs like nursing, health technicians, sports technologies, physiotherapy center, medical devices calibration center and home-care research center.
BioIzmir
BioIzmir is an international gateway project for creating a one-stop-shop ecosystem for biotech and medical devices. It is located within a health technopark (DEPARK) embedded into a hospital complex.
From design to manufacturing, process to IPR rights this will be a critical partner for companies and development/tech transfer organizations. Izmir Health Technologies Development and Accelerator Center will serve as a hub of the essential elements known in medical circle as “from the laboratory bench to the patient’s bedside”. The structure of the Center will provide “one-stop-shop” aimed to establish Izmir as the intersection of health enterprise and innovation in regional, national and international contexts. The activities within the scope of the project will create an eco system in which integration occurs between the industry and the dynamics of R&D and innovation.
iBG-izmir
Dokuz Eylul University Izmir Biomedicine and Genome Center (iBG-izmir) is developed within “Bioİzmir” Science and Technology Park, which is the result of the innovative partnership of DEU Health Campus, the Faculty of Medicine & University Hospital and the Health Themed Technopark (DEPARK). iBG is the first such regional hub, with headquarters in Izmir, Turkey’s third largest city and a critical locomotive for growing Turkish economy, particularly within the health sector. iBG’s vision is to establish a most prominent center for health and life sicences in South-West Europe and MENA countries in a 10 years period. This comprehensive regional hub will be multidisciplinary in approach and shall bring molecular biology, genetics, medicine, pharmaceutical sciences, bioengineering, computer engineering and many other fields together. iBG-izmir will open its doors in 09-10 Sep 2015 with including Nobel session and reception.
Contact
Dokuz Eylül Üniversitesi İnciraltı Yerleşkesi Balçova
35340 İzmir Türkiye
Tel: +90 (232) 412 80 00
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a…
Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s…
Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s…
Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the…
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical…
Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95…
Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in…
In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning…
Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact…
AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership…
See our Cookie Privacy Policy Here